AMANDA BUSCHBACH: Open Payments
NPI 1255738332 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$311 in 14 payments from 9 companies in 2025. Trend: 2023 $400 · 2024 $308 · 2025 $311
Food & beverage: $311
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 3 | $69 |
| United Therapeutics Corporation | 2 | $64 |
| GENZYME CORPORATION | 2 | $43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38 |
| Calliditas Therapeutics US Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| ABBVIE INC. | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
Products named: DUPIXENT, ZERBAXA, Tyvaso, Remodulin, WINREVAIR, TARPEYO, JASCAYD, OFEV.
Industry payments across AL — which companies pay providers there.
